Form D · Pharmaceuticals
Avant Sciences, Inc.
New York, NY · CIK 0002009739
Offering snapshot reported Jul 29, 2024 · SEC filing
- Reported sold
- $175K Offering amount: $300K
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Jan 12, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 29, 2024 | Initial | $175,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-519935
The Issuer in its discretion may increase the total offering amount by another $300,000.
Source: Form D, filed Jul 29, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Avnish Deobhakta | Director, Executive |
| Paul Lee | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
201 E. 86 Th Street Ste 7 D
New York, NY, 10028
New York, NY, 10028